Article citationsMore>>

Grey, A., Bolland, M.J., Wattie, D., Horne, A., Gamble, G. and Reid, I.R. (2009) The Antiresorptive Effects of a Single Dose of Zoledronate Persist for Two Years: A Randomized, Placebo-Controlled Trial in Osteopenic Postmenopausal Women. The Journal of Clinical Endocrinology & Metabolism, 94, 538-544.
https://doi.org/10.1210/jc.2008-2241

has been cited by the following article:

• TITLE: Bisphosphonates Zoledronate and Alendronate for the Management of Postmenopausal Osteoporosis

  AUTHORS: IsraaIsraa Ahmed Radwan, Nahed Sedky Korany, Bassant Adel Ezzat

  KEYWORDS: Bisphosphonates, Alendronate, Zoledronate, Postmenopausal Osteoporosis

  JOURNAL NAME: Case Reports in Clinical Medicine, Vol.7 No.5, May 10, 2018

  ABSTRACT: Bisphosphonates are among the most frequently used antiresorptive drugs for the management of postmenopausal osteoporosis. We review here two of the commonly used bisphosphonates zoledronate and alendronate.